Edesa Biotech, Inc.
NASDAQ:EDSABiotechnology
+$0.09 today
- Market cap
- $55.39M
- Beta
- 1.07
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.27
Volume 0.07M
Average 0.62M
EDSA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Edesa Biotech, Inc.NASDAQ: EDSA
Free Cash Flow · Q2 FY2026 · quarter ended Mar 2026
Free cash flow dips below year-ago levels
Q2 FY2026 free cash flow of $2.05M (cash outflow) fell 12.1% year over year, behind the +34.9% change in trailing-twelve-month free cash flow. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at -15.8% a year.
Context
- Free cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -12.1% toward the trailing-twelve-month pace of +34.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (7.32M) USD
- Year-over-year change
- -49.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (7.32M) | -49.7% |
| FY2024 | 2024-09-30 | (4.89M) | +26.3% |
| FY2023 | 2023-09-30 | (6.64M) | +46.0% |
| FY2022 | 2022-09-30 | (12.28M) | +10.1% |
| FY2021 | 2021-09-30 | (13.67M) | — |
Free Cash Flow vs competitors
How EDSA compares with its peers on the latest reported figures
- EDSA's LTM Mar 2026 free cash flow of $7.65M is the smallest of the 2 companies compared; the peer median is $15.52M.
- Its year-over-year change of +34.9% is the highest of 2, against a peer median of +23.8%.
- Over three fiscal years its annual growth of -15.8% compares with a peer median of +10.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.52M | +23.8% | +10.8% | — | |
| LTM Mar 2026 | $7.65M | +34.9% | -15.8% | — | |
| Peer median (excluding EDSA) | $15.52M | +23.8% | +10.8% | — | |
Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.19M) |
| Depreciation & Amortization | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| Deferred Income Tax | (3.31M) | (2.38M) | (308K) | 0 | 0 |
| Stock-Based Compensation | 3.2M | 2.26M | 1.25M | 537.49K | 729.64K |
| Change in Working Capital | (3.64M) | 2.89M | 308K | 571.07K | (985.65K) |
| Accounts Receivables | (3.23M) | 2.03B | 562.77K | 356.34K | (377.99K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (124.72K) | 882.84K | (556.27K) | 0 | 0 |
| Other Working Capital | (281.36K) | (2.03B) | 301.5K | 214.73K | (607.67K) |
| Other Non-Cash Items | 3.31M | 2.38M | 308K | (14.77K) | 0 |
| Operating Cash Flow | (13.66M) | (12.28M) | (6.64M) | (4.89M) | (7.32M) |
| Capital Expenditures | (6.15K) | (5.66K) | 3 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (3) | 0 | 0 |
| Investing Cash Flow | (6.15K) | (5.66K) | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | (29.53K) | 0 |
| Common Stock Issued | 14.17M | 11.63M | 4.83M | 621.56K | 17.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 14.17M | 11.63M | 4.83M | 592.03K | 17.03M |
| Effect of Forex Changes | 121.9K | (93.01K) | 76.85K | (25.9K) | 46.22K |
| Net Change in Cash | 625.56K | (748.34K) | (1.73M) | (4.32M) | 9.75M |
| Free Cash Flow | (13.67M) | (12.28M) | (6.64M) | (4.89M) | (7.32M) |
Edesa Biotech, Inc.
NASDAQ:EDSA
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.